Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 18/20 | 0.64 |
| ▸ | PPARA | Q07869 | 16/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18321310 | 0.98 | PPARG (0.62) | PPARGPPARAALDH1A1 | |
| SCHEMBL4187184 | 0.84 | LDHA (0.61) | PPARGPPARA | |
| SCHEMBL4170587 | 0.83 | PPARG (0.57) | PPARGPPARA | |
| SCHEMBL4173522 | 0.82 | PPARG (0.68) | PPARGPPARA | |
| SCHEMBL4183099 | 0.82 | PPARG (0.46) | PPARGPPARA | |
| SCHEMBL8935658 | 0.82 | PPARG (0.64) | PPARGPPARAALDH1A1 | |
| SCHEMBL8935654 | 0.82 | PPARG (0.64) | PPARGPPARAALDH1A1 | |
| SCHEMBL2106689 | 0.79 | PPARG (0.63) | PPARGPPARAALDH1A1 | |
| SCHEMBL28745487 | 0.79 | PPARG (0.63) | PPARGPPARAALDH1A1 | |
| SCHEMBL8864038 | 0.78 | CTRC (0.57) | PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227680-A1 | Amino Acid Derivatives | PFIZER, INC. (US) | 2009-09-10 | — | — | US | claimed |
| EP-1951655-A2 | AMINO ACID DERIVATIVES | Pfizer Limited (GB) | 2008-08-06 | — | — | EP | claimed |
| WO-2007057767-A2 | AMINO ACID DERIVATIVES | PFIZER LIMITED (GB) | 2007-05-24 | — | — | WO | claimed |
| US-11730714-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2023-08-22 | — | — | US | disclosed |
| US-11730714-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2023-08-22 | — | — | US | disclosed |
| US-11147788-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2021-10-19 | — | — | US | disclosed |
| EP-3307262-B1 | COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS | NMD PHARMA AS (DK) | 2021-05-19 | — | — | EP | disclosed |
| US-10934244-B2 | Compounds for use in treating neuromuscular disorders | NMD PHARMA A/S (DK) | 2021-03-02 | — | — | US | disclosed |
| US-10385028-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2019-08-20 | — | — | US | disclosed |
| US-20190183863-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | US | disclosed |
| US-20190183833-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA APS | 2019-06-20 | — | — | US | disclosed |
| US-20190183812-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | US | disclosed |
| US-20190185437-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA APS (DK) | 2019-06-20 | — | — | US | disclosed |
| US-20190183834-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | US | disclosed |
| US-20180099920-A1 | COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS | NMD PHARMA APS (DK) | 2018-04-12 | — | — | US | disclosed |
| US-20180099920-A1 | COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS | NMD PHARMA APS (DK) | 2018-04-12 | — | — | US | disclosed |
| WO-2016202341-A1 | COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS | NMD PHARMA APS (DK) | 2016-12-22 | — | — | WO | disclosed |
| US-20090227680-A1 | Amino Acid Derivatives | PFIZER, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| EP-1951655-A2 | AMINO ACID DERIVATIVES | Pfizer Limited (GB) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007057767-A2 | AMINO ACID DERIVATIVES | PFIZER LIMITED (GB) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11730714-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, RYR2 | PPARG 3332/4885PPARA 3247/4885ALDH1A1 1343/4885 |
| US-20090227680-A1 | Amino Acid Derivatives | OPRL1, OPRK1, AVPR1A | PPARG 2322/4885PPARA 1589/4885ALDH1A1 851/4885 |
| US-10934244-B2 | Compounds for use in treating neuromuscular disorders | CPT1B, CLCN2, TNNC1 | PPARG 2105/4885PPARA 2774/4885ALDH1A1 1498/4885 |
| US-20190183834-A1 | Compounds For The Treatment Of Neuromuscular Disorders | RYR1, CACNB1, RYR2 | PPARG 3332/4885PPARA 3247/4885ALDH1A1 1343/4885 |
| US-20180099920-A1 | COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS | CPT1B, CLCN2, TNNC1 | PPARG 2105/4885PPARA 2774/4885ALDH1A1 1498/4885 |
| US-20190183812-A1 | Compounds For The Treatment Of Neuromuscular Disorders | RYR1, CACNB1, RYR2 | PPARG 3332/4885PPARA 3247/4885ALDH1A1 1343/4885 |
| US-11147788-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, RYR2 | PPARG 3332/4885PPARA 3247/4885ALDH1A1 1343/4885 |
| US-10385028-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, RYR2 | PPARG 3332/4885PPARA 3247/4885ALDH1A1 1343/4885 |
| US-20190183863-A1 | Compounds For The Treatment Of Neuromuscular Disorders | RYR1, CACNB1, RYR2 | PPARG 3332/4885PPARA 3247/4885ALDH1A1 1343/4885 |
| US-20190185437-A1 | Compounds For The Treatment Of Neuromuscular Disorders | CLCN2, SCN1B, CACNB1 | PPARG 3152/4885PPARA 3651/4885ALDH1A1 1891/4885 |
| US-20190183833-A1 | Compounds For The Treatment Of Neuromuscular Disorders | RYR1, CACNB1, RYR2 | PPARG 3332/4885PPARA 3247/4885ALDH1A1 1343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.